Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacia e sicurezza dell'iniezione sottocutanea di XH-02 nel trattamento dell'ipoparatiroidismo negli adulti

23 settembre 2026 aggiornato da: Yan Qin, Peking Union Medical College Hospital

Efficacia e sicurezza dell'iniezione sottocutanea del farmaco ad acido nucleico mRNA XH-02 nel trattamento dell'ipoparatiroidismo negli adulti

XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Animal studies have shown pharmacodynamic effects of XH-02, with a favorable safety profile. A clinical study of intravenously administered XH-02 has been completed in patients with hypoparathyroidism, yielding clear pharmacodynamic results and demonstrating good safety. This study aims to evaluate the safety and efficacy of subcutaneously injected XH-02 in patients with hypoparathyroidism.

Panoramica dello studio

Stato

Sospeso

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

15

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100730
        • Peking Union Medical College Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Aged 18-65 years (inclusive of 18 and 65), male or female.
  2. A history of postoperative chronic hypoparathyroidism (HP) or autoimmune, genetic, or idiopathic HP for at least 26 weeks. HP is confirmed based on a previous occurrence of hypocalcemia accompanied by an inappropriately low serum parathyroid hormone (PTH) level (below the upper limit of the local laboratory's normal range). Note: If the subject does not have a documented diagnosis of chronic HP but has experienced hypocalcemia accompanied by an inappropriately low serum PTH level for at least 26 weeks prior to screening, and the investigator determines that the diagnosis of chronic HP is met, this criterion is considered fulfilled.
  3. Inadequate control of hypoparathyroidism with conventional treatment (calcium and vitamin D) or intolerance to such treatment.
  4. At screening, Body Mass Index (BMI) of 17-40 kg/m² (inclusive).
  5. If aged ≤25 years, radiographic evidence of epiphyseal closure based on X-ray examination of the wrist and hand of the non-dominant hand.
  6. At screening, conventional therapy may be optimized to achieve: serum 25-hydroxyvitamin D [25(OH)D] 10-100 ng/mL; serum magnesium and albumin-corrected serum calcium within or slightly below the normal range.

Exclusion Criteria:

  1. Impaired response to PTH (pseudohypoparathyroidism), characterized by resistance to PTH and elevated PTH levels during hypocalcemia.
  2. Known allergies, or a history of allergy to the investigational drug or polyethylene glycol (PEG).
  3. Any disease other than HP that may affect calcium metabolism, calcium-phosphorus homeostasis, or PTH levels, such as active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; Type 1 diabetes mellitus or poorly controlled Type 2 diabetes mellitus (HbA1C >9%, HbA1C test results from blood samples collected within 12 weeks prior to screening are acceptable); severe and chronic liver or kidney disease; Cushing's syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobilization; active malignancy (except for low-risk well-differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; history of parathyroid cancer within 5 years prior to screening; acromegaly; or multiple endocrine neoplasia.
  4. History of vaccination within 4 weeks prior to enrollment, or planned vaccination during the study period.
  5. Women who are pregnant or breastfeeding.
  6. Patients with high-risk thyroid cancer requiring TSH suppression to <0.2 mIU/L within the past 2 years, or those with a history of malignancy.
  7. Subjects requiring long-term use of diuretics, phosphate binders (except calcium supplements), digoxin, lithium, methotrexate, biotin >30 μg/day, or systemic corticosteroids (except as replacement therapy). Patients requiring long-term use of hormones or immunosuppressants (e.g., for rheumatic or autoimmune diseases) will not be enrolled in this study. Note: Subjects who can discontinue these medications during the study may be enrolled, but they must be discontinued for at least 5.5 half-lives prior to Visit 1 blood sample collection. Biotin must be discontinued for at least 1 day prior to screening blood sample collection. These medications are prohibited throughout the study.
  8. Use of PTH-like drugs (either commercially available or obtained through participation in a clinical trial), including PTH (1-84), PTH (1-34), or other N-terminal fragments or analogs of PTH, or PTH-related protein, within 4 weeks prior to screening.
  9. Participation in any other interventional trial and receipt of investigational drug or device within 8 weeks prior to screening, or still within 5.5 half-lives of the drug from a previously participated trial.
  10. Presence of uncontrolled hypertension at baseline, or a history of the following cardiovascular or cerebrovascular diseases, including: (1) Unstable angina; (2) Arrhythmia requiring medication or severe arrhythmia; (3) Myocardial infarction; (4) Class III or higher heart failure (per NYHA classification), second-degree or higher atrioventricular block; (5) Cerebral infarction (except lacunar infarction), cerebral hemorrhage, or other such conditions.
  11. Increased risk of osteosarcoma, for example, having Paget's disease of bone or unexplained elevated alkaline phosphatase, genetic disorders predisposing to osteosarcoma, or previous exposure to high-dose external beam radiation or implant radiotherapy to the skeleton.
  12. Abnormal laboratory test results meeting any of the following criteria: Blood routine: Neutrophil count (NEUT#) <1.5×10⁹/L; Platelet count (PLT) <90×10⁹/L; Hemoglobin (Hb) <90g/L; Eosinophil count (EOS#) >0.5×10⁹/L. Liver and kidney function: Total bilirubin or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding the normal range; eGFR <60 ml/min/1.73m².
  13. Any other medical or other condition that, in the investigator's judgment, might affect the conduct of the study or interfere with the study results, or might increase the risk to the subject.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Single dose (40 μg)

Participants will receive a single subcutaneous dose of 40 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Single dose (80 μg)

Participants will receive a single subcutaneous dose of 80 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Single dose (120 μg)

Participants will receive a single subcutaneous dose of 120 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Multiple doses (20 µg)

Participants will receive a daily subcutaneous injection of 20 µg of XH-02 for 5 consecutive days

Participants will receive once daily subcutaneous injection of XH-02 for 5 consecutive days.

Sperimentale: Multiple doses (40 µg)

Participants will receive a daily subcutaneous injection of 40 µg of XH-02 for 5 consecutive days

Participants will receive once daily subcutaneous injection of XH-02 for 5 consecutive days.

Sperimentale: Multiple doses (60 µg)

Participants will receive a daily subcutaneous injection of 60 µg of XH-02 for 5 consecutive days

Participants will receive once daily subcutaneous injection of XH-02 for 5 consecutive days.

Sperimentale: Multiple doses (80 µg)

Participants will receive a daily subcutaneous injection of 80 µg of XH-02 for 5 consecutive days

Participants will receive once daily subcutaneous injection of XH-02 for 5 consecutive days.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Adverse events (safety)
Lasso di tempo: From the first dose through 30 days after the last dose for non-serious adverse events, and through 3 months after the last dose for severe adverse events.

Adverse events, including serious adverse events.

Assessment methods:

spontaneous reports; scheduled laboratory tests (hematology, chemistry, C-reactive protein, urinalysis); vital signs (blood pressure, heart rate, respiratory rate, temparature), physical examinations, and electrocardiogram (QTc interval, arrhythmia).

From the first dose through 30 days after the last dose for non-serious adverse events, and through 3 months after the last dose for severe adverse events.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PTH(1-84) (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before administration), and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose.

serum PTH(1-84)

Single dose: Predose (within one hour before administration), and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose.
PTH (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before administration), and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose

serum PTH

Single dose: Predose (within one hour before administration), and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose
Serum calcium (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before administration), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose

Serum calcium

Single dose: Predose (within one hour before administration), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose
Serum phosphorus (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before administration), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose

Serum phosphorus

Single dose: Predose (within one hour before administration), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose
Serum magnesium (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before administration), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose

Serum magnesium

Single dose: Predose (within one hour before administration), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose
1, 25-Dihydroxyvitamin D3 (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before administration); and 24, 48, and 72 hours postdose. Multiple dose: Predose on Day 1, Day 3, Day 5; and 48 hours and 72 hours after the last dose.

Serum 1, 25-Dihydroxyvitamin D3

Single dose: Predose (within one hour before administration); and 24, 48, and 72 hours postdose. Multiple dose: Predose on Day 1, Day 3, Day 5; and 48 hours and 72 hours after the last dose.
24-hour urine calcium (efficacy)
Lasso di tempo: Single dose: Predose (within 3 days before administration), and 24, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose), and 24, 48, and 72 hours after the last dose

24-hour urine calcium (24hUCa)

Single dose: Predose (within 3 days before administration), and 24, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose), and 24, 48, and 72 hours after the last dose
Fractional Excretion of calcium (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before administration), and 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose), and 24, 48, and 72 hours after the last dose

Fractional Excretion of calcium (FECa)

Single dose: Predose (within one hour before administration), and 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose on Day 1 to 5 (before each dose), and 24, 48, and 72 hours after the last dose

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Procollagen type 1 N-terminal propeptide (Exploratory endpoint)
Lasso di tempo: Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose

Serum Procollagen type 1 N-terminal propeptide (P1NP)

Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose
Beta-isomerized C-terminal telopeptide of type 1 collagen (Exploratory endpoint)
Lasso di tempo: Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose

Serum Beta-isomerized C-terminal telopeptide of type 1 collagen (β-CTX)

Multiple dose: Predose on Day 1 to 5 (before each dose); and 24, 48, and 72 hours after the last dose

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Yan Qin, Peking Union Medical College Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 novembre 2025

Completamento primario (Stimato)

30 maggio 2027

Completamento dello studio (Stimato)

30 agosto 2027

Date di iscrizione allo studio

Primo inviato

1 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 aprile 2026

Primo Inserito (Effettivo)

15 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 aprile 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • K9040

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

The investigators do not plan to share Individual Participant Data (IPD) due to confidentiality agreements and participant privacy commitments.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .